Navigation Links
Anacor Pharmaceuticals Announces Positive Results from Phase 2a Clinical Trial of AN2728 in Psoriasis Patients
Date:3/25/2008

on drug efficacy. These earlier trials demonstrated significant activity even at a 0.5% concentration of AN2728, the lowest concentration tested.

About Psoriasis

Affecting approximately 10 million people worldwide, psoriasis is an inflammation of the skin caused by a reaction of the immune system. It is characterized by thickened patches of inflamed, red skin covered with thick, silvery scales typically found at the elbows, knees, scalp and genital areas.

About Anacor Pharmaceuticals

Anacor is a biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform. Anacor has focused initially on developing topical applications of its compounds to treat fungal, bacterial and inflammatory diseases. Anacor's most advanced product candidate is AN2690, a novel topical antifungal in development for the treatment of toenail onychomycosis, which is a fungal infection of the nail and nail bed. Anacor entered into a worldwide license, development and commercialization agreement for AN2690 with Schering-Plough for all indications including the treatment of onychomycosis. Anacor also has a research and development collaboration with GlaxoSmithKline for the discovery, development, manufacture and worldwide commercialization of novel systemic therapeutics for viral and bacterial diseases utilizing Anacor's boron-based chemistry. For more information visit http://www.anacor.com.

Forward-Looking Statements

This press release contains forward-looking statements, including statements regarding the progress and timing of our clinical trials and the safety and efficacy of our product candidates. These statements relate to future events and involve known and unknown risks, uncertainties and other factors that could cause actual levels of activity, performance or achievement to differ materially from those expressed or implied by these forward-looking st
'/>"/>

SOURCE Anacor Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. NuRx Pharmaceuticals Doses First Patient in Phase I Clinical Trial of First-in-Class RXR Agonist NRX4204
2. MAP Pharmaceuticals Reports Positive Results From Comparative Pharmacokinetic Trial for its Pediatric Asthma Product Candidate
3. VIA Pharmaceuticals Completes Enrollment In Phase 2 Carotid Endarterectomy (CEA) Trial
4. Poniard Pharmaceuticals Announces Clinical Data From Picoplatin Oral Phase 1 to Be Presented at the American Association of Cancer Research Annual Meeting
5. BioNumerik Pharmaceuticals and ASKA Pharmaceutical Co. Announce Results from Phase III Clinical Trial of Tavocept(TM)
6. Merrimack Pharmaceuticals Completes Enrollment in a Phase 2 Study of MM-093 in Patients with Rheumatoid Arthritis
7. Access Pharmaceuticals to Conduct Conference Call to Update Financial Community
8. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
9. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
10. AlphaMed Pharmaceuticals Announces Breakthrough in the Development of Recombinant Alpha 1-Antitrypsin
11. Memory Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2008)... REINACH, Switzerland, November 20 /PRNewswire... that the Anti-infective Drugs Advisory Committee ...s voted 17 to 2 against the,approval of intraveno...t for,the treatment of patients with complicated ...uding those caused by methicillin-resistant Staphy...
(Date:11/20/2008)... LA JOLLA, Calif., Nov. 20 /PRNewswire-FirstCall/ ... DSKA), announced today that it has submitted its,...r review under a Special,Protocol Assessment (SPA...tion,(FDA). , Subject to securing an agree...ngle, prospective, double-blind, placebo-controlle...
(Date:11/20/2008)... BOSTON, Nov. 20 PAREXEL...ading global biopharmaceutical services provider, ...ma, Peru to provide regulatory consulting and clin...he Peru office, PAREXEL now has locations througho...in America, which also include Argentina, Brazil, ...
(Date:11/19/2008)... THOUSAND OAKS, Calif., Nov. 19 /PRNewswire-FirstC...he Takeda Oncology Company, a subsidiary of,Taked...y announced that,enrollment in the Phase 3 MONET1...ion with paclitaxel and carboplatin for the first-...ncer (NSCLC) has been temporarily suspended,follo...
Breaking Medicine Technology:Arpida Comments on FDA's Anti-infective Drugs Advisory Committee Outcome 2Arpida Comments on FDA's Anti-infective Drugs Advisory Committee Outcome 3Arpida Comments on FDA's Anti-infective Drugs Advisory Committee Outcome 4Duska Therapeutics Applies for Phase 3 Special Protocol Assessment 2Duska Therapeutics Applies for Phase 3 Special Protocol Assessment 3Duska Therapeutics Applies for Phase 3 Special Protocol Assessment 4PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru 2PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru 3PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru 4Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 2Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 3Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 4Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 5Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 6Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 7High Blood Pressure May Heighten Effects of Alzheimers Disease 934 1High Blood Pressure May Heighten Effects of Alzheimers Disease 934 2Transporters may help delay diabetes related retinal damage 7116 1Transporters may help delay diabetes related retinal damage 7116 2Transporters may help delay diabetes related retinal damage 7116 3Nanotechnology and the media 3A The inside story 1364 1Nanotechnology and the media 3A The inside story 1364 2Promising Data ATIR Studies Presented by NIH Investigators 1980 1Promising Data ATIR Studies Presented by NIH Investigators 1980 2
(Date:11/22/2008)... Open enrollment is now happ...over expenses not covered by Medicare, and may als... consumers are now shopping online for instant quo...ort Collins, CO (PRWEB) November 21, 2008 -- MediG... for Medicare Supplement plans . Medicare Advant...
(Date:11/21/2008)...NGE COUNTY, Calif., Nov. 21 Album ...ting firm, launches a new program offering big bra...have taken the large, expensive ad agency process ...s with a very hands-on approach," says Matt Parker... 2002, combines experience and proven brand-buildi...
(Date:11/21/2008)...s, parents and schools need to work together to st...DAY, Nov. 21 (HealthDay News) -- Behavior that was...ized as bullying. , And as mounting research sh... victim, mental-health professionals, schools, par...ew ways to combat this threatening behavior. ,...
(Date:11/21/2008)... TALLAHASSEE, Fla. -- A Florida State University C...ang has discovered an important new layer of regul... to a greater understanding of the way cancer begi... sciences at the College of Medicine, said the fin... cancer and could lead to the design of new drugs ...
Breaking Medicine News(10 mins):Health News:MediGap Advisors Announces Open Enrollment for Medicare Supplement Plans 2Health News:Album Creative Studios Tailors Big Brand Marketing For Small Businesses 2Health News:Getting Tough on Bullying 2Health News:Getting Tough on Bullying 3
...growth of colon polyps to half, it doubles the ris...by two significant studies published in the Aug. 3...e opinions of Bruce M. Psaty, M.D., Ph.D., and Joh...iversity of Washington were also published along w...
... only reverses the arterial dysfunction caused by ...ame arteries compared to before the meal, accordin...dings, reported in the European Journal of Applied...us on the effect food has on the body after the me...
...reas preoperative brain could effectively alter th...pear in the September issue of Radiology, states t...uage areas of the brain with functional magnetic r...e surgeons in pinpointing the brain tumors more ef...
...as challenged the view of The Sterling Council, of...alarm service, which the// Scottish public service...minced words that the ruling is a target at the we...ruly a mockery of the free care provided for the e...
Other Medicine News:Health News:Celebrex- pros and cons 2Health News:A Serving of Exercise After That Saturated Fat 2Health News:fMRI Prior to surgery Could Help In Outcome Of Tumor Surgery 2Health News:fMRI Prior to surgery Could Help In Outcome Of Tumor Surgery 3
Bandeau Bra
Bras and Breast Support
Compression Bra
Constructed from soft Shur-grip foam and velcro closure for easy application and - reapplication
Medicine Products: